Gelteq Limited (GELS) Balance Sheet

NASDAQ: GELSAssets, liabilities, debt and equity over 6 years.

GELS balance sheet, FY2025

June 30, 2025 · Australian dollars

A$21.5M assets = A$5.7M liabilities + A$15.8M equity

What it ownsA$21.5MCash & ST investments: A$344,648 (1.6%)Receivables: A$459,724 (2.1%)Other current: A$702,298 (3.3%)PP&E: A$15,907 (0.1%)Goodwill & intangibles: A$19.9M (92.5%)Goodwill & intangiblesA$19.9M · 92%Other non-current: A$94,605 (0.4%)=How it is financedA$21.5MCurrent liabilities: A$5.6M (26.2%)Current liabilitiesA$5.6M · 26%Long-term debt: A$13,550 (0.1%)Other LT liabilities: A$24,992 (0.1%)Shareholders’ equity: A$15.8M (73.6%)Shareholders’ equityA$15.8M · 74%

Both columns are drawn to the same scale: what GELS owns equals what it owes plus shareholders’ equity. Hover a block for its value.

GELS financial health

Current ratio0.27
Tight · current assets cover current liabilities 0.27×
Debt / equity0.27
Low leverage · A$0.27 of debt for each $1 of equity
Equity / assets73.6%
Equity-funded · of assets funded by shareholders
Cash / debt8.2%
Low cash cover · cash & short-term investments vs total debt
Goodwill & intangibles92.5%
Mostly intangible · of total assets

Descriptive bands, not a rating. Fiscal FY2025.

GELS balance sheet trends, FY2020–FY2025

Gelteq Limited balance sheet trends
MetricTrendThenLatestChange
Total assetsA$619,115FY2020A$21.5MFY2025+103.3%/yr
Total liabilitiesA$396,043FY2020A$5.7MFY2025+70.3%/yr
Shareholders’ equityA$223,072FY2020A$15.8MFY2025+134.5%/yr
Cash & short-term investmentsA$319,519FY2020A$344,648FY2025+1.5%/yr
Total debtA$170,703FY2020A$4.2MFY2025+89.9%/yr
Net cash (debt)A$148,816FY2020−A$3.9MFY2025−A$4.0M
Working capitalA$344,562FY2020−A$4.1MFY2025−A$4.5M
Current ratio2.50FY20200.27FY2025−2.23
Debt / equity0.77FY20200.27FY2025−0.50
Shares outstanding2.3MFY202010.0MFY2025+33.7%/yr

Change is the average annual growth (CAGR) or the difference between the first and latest year.

GELS assets

Cash & ST investmentsReceivablesInventoryOther currentPP&EGoodwill & intangiblesLT investmentsOther non-current

GELS liabilities and equity

Current liabilitiesLong-term debtOther long-term liabilitiesEquity

GELS debt vs cash

Total debtCash & ST investmentsNet cash (debt)

Debt includes short- and long-term borrowings and, where reported, lease obligations.

GELS balance sheet in Australian dollars

Gelteq Limited annual balance sheet
FY2025FY2024FY2023FY2022FY2021FY2020
Assets
Cash & short-term investmentsA$344,648A$24,522A$399,224A$162,485A$181,664A$319,519
Cash & equivalentsA$344,648A$24,522A$399,224A$162,485A$181,664A$319,519
ReceivablesA$459,724A$183,005A$345,291A$250,666A$193,245A$254,978
InventoryA$0A$0A$95,201A$95,201A$0A$0
Other current assetsA$702,298A$95,700A$151,258A$211,713A$0A$0
Total current assetsA$1.5MA$303,227A$990,974A$720,065A$374,909A$574,497
Property, plant & equipment (net)A$15,907A$16,642A$10,000A$40,004A$0A$0
Goodwill & intangible assetsA$19.9MA$20.4MA$21.5MA$22.6MA$23.8MA$44,618
Long-term investmentsA$0A$0A$0A$0A$0A$0
Other non-current assetsA$94,605A$0A$1A$0A$0A$0
Total assetsA$21.5MA$20.8MA$22.5MA$23.4MA$24.2MA$619,115
Liabilities
Accounts payableA$182,632A$387,034A$291,270A$216,725A$85,128A$170,340
Short-term debtA$4.2MA$2.1MA$16,982A$39,793A$4,796A$4,595
Deferred revenue—A$125,359A$85,359A$119,765——
Total current liabilitiesA$5.6MA$3.9MA$1.4MA$1.1MA$235,900A$229,935
Long-term debtA$13,550A$1.8MA$2.5MA$1.5MA$167,328A$0
Lease obligations—A$0A$11,896A$46,603A$0—
Other long-term liabilitiesA$24,992A$20,018A$0A$11,896A$0A$166,108
Total liabilitiesA$5.7MA$5.6MA$3.8MA$2.6MA$403,228A$396,043
Shareholders' equity
Common stock & paid-in capitalA$33.9MA$26.6MA$26.6MA$25.3MA$24.9MA$300,233
Retained earnings (deficit)−A$18.1M−A$11.5M−A$7.9M−A$4.5M−A$1.1M−A$460,425
Accumulated other comprehensive income———A$34,722——
Total shareholders' equityA$15.8MA$15.1MA$18.7MA$20.9MA$23.8MA$223,072
Key figures
Total debtA$4.2MA$3.8MA$2.5MA$1.5MA$172,124A$170,703
Net cash (debt)−A$3.9M−A$3.8M−A$2.1M−A$1.3MA$9,540A$148,816
Working capital−A$4.1M−A$3.6M−A$373,551−A$360,895A$139,009A$344,562
Tangible book value−A$4.1M−A$5.3M−A$2.8M−A$1.8M−A$28,319A$178,454
Shares outstanding10.0M9.4M9.4M9.4M9.4M2.3M
Current ratio0.270.080.730.671.592.50
Quick ratio0.140.050.550.381.592.50
Debt / equity0.270.250.130.070.010.77
Equity / assets73.6%72.8%82.9%89.1%98.3%36.0%

Quarterly columns are labeled by the month the quarter ended. Figures in Australian dollars as reported (latest annual report filed June 30, 2025); data from EODHD.

GELS financial position

At the end of fiscal 2025 (June 30, 2025), Gelteq had total assets of A$21.5 million (up 3.5% from a year earlier), total liabilities of A$5.7 million and shareholders' equity of A$15.8 million. It held A$0.3 million in cash and short-term investments against A$4.2 million of debt, net debt of A$3.9 million. Its current ratio was 0.27. In the latest quarter (ended March 31, 2026) total assets were A$20.1 million and equity A$14.2 million.

Related: GELS income statement, GELS cash flow statement, GELS key metrics. See the GELS stock overview for the latest quote and news.

GELS balance sheet FAQ

What are Gelteq's total assets?

Gelteq reported total assets of A$21.5 million at the end of fiscal 2025 (June 30, 2025), compared with A$20.8 million a year earlier.

How much debt does Gelteq have?

Gelteq had A$4.2 million of total debt at the end of fiscal 2025, including short-term borrowings. Its debt-to-equity ratio was 0.27.

How much cash does Gelteq have?

Gelteq held A$0.3 million in cash and short-term investments at the end of fiscal 2025; with A$4.2 million of debt that is net debt of A$3.9 million.

What is Gelteq's book value?

Gelteq's shareholders' equity (book value) was A$15.8 million at the end of fiscal 2025.

What is Gelteq's current ratio?

Gelteq had current assets of A$1.5 million and current liabilities of A$5.6 million, a current ratio of 0.27 (current liabilities exceed current assets).

How much goodwill does Gelteq have?

Gelteq carried A$19.9 million of goodwill and intangible assets, 92.5% of total assets, at the end of fiscal 2025.

Drug Manufacturers - Specialty & Generic: balance sheet